enGene Therapeutics Inc 10-Q for FY2026 Q3
enGene Therapeutics Inc. (ENGN)
10-Q
2026-09-08
For: 2026-07-31
View Original
Added on
September 08, 2026
About this 10-Q
enGene Therapeutics Inc filed this 10-Q on September 8, 2026, covering the quarter ended July 31, 2026 (FY2026 Q3).
Headline figures
Quarter ended July 31, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $32.5M
- compared with a net loss of $28.99M a year earlier
- Diluted EPS
- -$0.47
- compared with -$0.57 a year earlier